Hedge Funds Place Record Bets Against Bavarian Nordic

Updated on
  • Short positions on biotech firm surged to 11% in recent weeks
  • Prostate cancer trial is a major binary event, Jefferies says

After fighting off a vocal attack from a short seller less than a year ago, Bavarian Nordic A/S is again the target of hedge funds betting shares in the Danish biotechnology company are set to fall.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.